[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522685":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":119,"collaborators":20,"id":121,"slug":122,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":123,"sex":129,"minAge":130,"maxAge":20,"enrollmentInfo":131,"targetDuration":20,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"ARTIDIS AG","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Human subjects requiring breast biopsy","OTHER","All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy are eligible for this study. Upon consent, a diagnostic biopsy will be measured by the sponsor's device before returning to the standard of care pathway.",[13],"Diagnostic Test: Nanomechanical Phenotype Test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Nanomechanical Phenotype Test","The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Alastair Thompson, MD","Baylor College of Medicine","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Julia Ortega, DMSc, MHS, PA","CONTACT","2404980176","julia.ortega@artidis.com",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Marko Loparic, MD,PhD","+41 61 633 29 95","Marko.Loparic@artidis.com",[37,58,71,83,101],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Texas Southwestern Medical Center","RECRUITING","Dallas","Texas","75390-9020","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-96.80667,32.78306,{"lat":49,"lon":48},[52,56],{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Research Manager","214-645-1568","Claire.Starcke@UTSouthwestern.edu",{"name":57,"role":25,"phone":20,"phoneExt":20,"email":20},"Basak Dogan, MD",{"facility":24,"status":39,"city":59,"state":41,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Houston","77030",{"type":46,"coordinates":62},[63,64],-95.36327,29.76328,{"lat":64,"lon":63},[67,70],{"name":23,"role":29,"phone":68,"phoneExt":20,"email":69},"7137981999","Alastair.Thompson@bcm.edu",{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"facility":72,"status":39,"city":59,"state":41,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"MD Anderson Cancer Clinic - Mays Clinic",{"type":46,"coordinates":74},[63,64],{"lat":64,"lon":63},[77,81],{"name":78,"role":29,"phone":79,"phoneExt":20,"email":80},"Research Manager, MD","713-745-8048","DWeber@mdanderson.org",{"name":82,"role":25,"phone":20,"phoneExt":20,"email":20},"Therese Bevers",{"facility":84,"status":39,"city":85,"state":85,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Hospital Universitario Vall d'Hebron","Barcelona","08035","Spain","ES",{"type":46,"coordinates":90},[91,92],2.15899,41.38879,{"lat":92,"lon":91},[95,99],{"name":96,"role":29,"phone":97,"phoneExt":20,"email":98},"Sonia Borao Arriazu","+34 93 489 30 00","sonia.borao@vhir.org",{"name":100,"role":25,"phone":20,"phoneExt":20,"email":20},"Vicente Peg, MD.PhD",{"facility":102,"status":39,"city":103,"state":103,"zip":104,"country":105,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Claraspital","Basel","CH-4058","Switzerland","CH",{"type":46,"coordinates":108},[109,110],7.57327,47.55839,{"lat":110,"lon":109},[113,117],{"name":114,"role":29,"phone":115,"phoneExt":20,"email":116},"Study Coordinator","+41 61 685 89 09","catherine.punsola@claraspital.ch",{"name":118,"role":25,"phone":20,"phoneExt":20,"email":20},"Roberto Rodriguez, MD",{"type":120,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100522685","artidis-nanomechanical-generated-measurements-for-early-breast-lesions-100522685",false,"NCT06085833","ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions","ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL)","ANGEL","Inclusion Criteria:\n\n* Patients aged ≥ 18 years\n* Ability to understand and the willingness to sign a written informed consent.\n* Indication for breast biopsy for diagnostic purposes\n* ECOG performance status of 0 to 3.\n\nExclusion Criteria:\n\n* Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.","ALL","18 Years",{"count":132,"type":133},2706,"ESTIMATED","INTERVENTIONAL",[136],"NA","This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.",[139],"Breast Cancer",[141,142],"Breast biopsy","breast cancer","2026-04-14",{"date":145,"type":146},"2026-04-17","ACTUAL",{"date":148,"type":146},"2023-11-02",{"date":150,"type":133},"2035-11",{"name":5,"class":6},5]